Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Pharmacovirological analyses of blood and male genital compartment in patients receiving dolutegravir + lamivudine dual therapy as a switch strategy (ANRS 167 LAMIDOL trial).

Charpentier C, Peytavin G, Raffi F, Burdet C, Landman R, Lê MP, Katlama C, Collin G, Benalycherif A, Cabie A, Mentré F, Yazdanpanah Y, Descamps D, Joly V; ANRS 167 LAMIDOL Study Group .

J Antimicrob Chemother. 2020 Feb 24. pii: dkaa035. doi: 10.1093/jac/dkaa035. [Epub ahead of print]

PMID:
32091102
2.

Aspergillus flavus malignant external otitis in a diabetic patient: case report and literature review.

Pichon M, Joly V, Argy N, Houze S, Bretagne S, Alanio A, Wassef M, Verillaud B, Yazdanpanah Y.

Infection. 2020 Apr;48(2):193-203. doi: 10.1007/s15010-020-01394-8. Epub 2020 Feb 8. Review.

PMID:
32036556
3.

Pollination Type Recognition from a Distance by the Ovary Is Revealed Through a Global Transcriptomic Analysis.

Joly V, Tebbji F, Nantel A, Matton DP.

Plants (Basel). 2019 Jun 24;8(6). pii: E185. doi: 10.3390/plants8060185.

4.

The ScFRK2 mitogen-activated protein kinase kinase kinase (MAP3K) is involved in early embryo sac development in Solanum chacoense.

Mazin BD, Joly V, Matton DP.

Plant Signal Behav. 2019;14(8):1620059. doi: 10.1080/15592324.2019.1620059. Epub 2019 May 25.

PMID:
31131700
5.

HIV Infection in North African Patients.

Parisey M, Louni F, Bouvet E, Landman R, Charpentier C, Lariven S, Joly V, Villemant A, Mackoumbou-Nkouka C, Yazdanpanah Y, Burdet C.

AIDS Res Hum Retroviruses. 2019 Jul;35(7):628-633. doi: 10.1089/AID.2018.0292. Epub 2019 Jun 19.

6.

New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations.

Castain L, Perrier M, Charpentier C, Palich R, Desire N, Wirden M, Descamps D, Sayon S, Landman R, Valantin MA, Joly V, Peytavin G, Yazdanpanah Y, Katlama C, Calvez V, Marcelin AG, Todesco E.

J Antimicrob Chemother. 2019 Jul 1;74(7):2019-2023. doi: 10.1093/jac/dkz151.

PMID:
31050739
7.

Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection.

Gantner P, Cotte L, Allavena C, Bani-Sadr F, Huleux T, Duvivier C, Valantin MA, Jacomet C, Joly V, Chéret A, Pugliese P, Delobel P, Cabié A, Rey D; Dat’AIDS Study Group.

PLoS One. 2019 Apr 18;14(4):e0215464. doi: 10.1371/journal.pone.0215464. eCollection 2019.

8.

HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen.

Perrier M, Castain L, Regad L, Todesco E, Landman R, Visseaux B, Yazdanpanah Y, Rodriguez C, Joly V, Calvez V, Marcelin AG, Descamps D, Charpentier C.

J Antimicrob Chemother. 2019 Jun 1;74(6):1679-1692. doi: 10.1093/jac/dkz043.

PMID:
30768160
9.

Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL).

Joly V, Burdet C, Landman R, Vigan M, Charpentier C, Katlama C, Cabié A, Benalycherif A, Peytavin G, Yeni P, Mentre F, Argoud AL, Amri I, Descamps D, Yazdanpanah Y; LAMIDOL Study Group.

J Antimicrob Chemother. 2019 Mar 1;74(3):739-745. doi: 10.1093/jac/dky467.

PMID:
30476165
10.

Impact of Antiretroviral Drugs on Fracture Risk in HIV-Infected Individuals: A Case-Control Study Nested Within the French Hospital Database on HIV (FHDH-ANRS CO4).

Costagliola D, Potard V, Lang S, Abgrall S, Duvivier C, Fischer H, Joly V, Lacombe JM, Valantin MA, Mary-Krause M, Rozenberg S.

J Acquir Immune Defic Syndr. 2019 Feb 1;80(2):214-223. doi: 10.1097/QAI.0000000000001903.

11.

Which antiretrovirals should be prescribed as first-line treatments? Changes over the past 10 years in France.

Pugliese P, Joly V, Valantin MA, Cotte L, Huleux T, Allavena C, Reynes J, Poizot-Martin I, Bani-Sadr F, Cuzin L; Dat’AIDS group.

Med Mal Infect. 2019 Jun;49(4):264-269. doi: 10.1016/j.medmal.2018.10.005. Epub 2018 Nov 5.

PMID:
30409541
12.

A case of thoracic actinomycosis presenting as sudden paraplegia.

Peiffer-Smadja N, Harent S, Messeca C, Lechapt-Zalcman E, Yazdanpanah Y, Joly V.

Rev Neurol (Paris). 2019 Jan - Feb;175(1-2):89-92. doi: 10.1016/j.neurol.2018.01.380. Epub 2018 Oct 8. No abstract available.

PMID:
30309660
13.

Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients.

Allavena C, Hanf M, Rey D, Duvivier C, BaniSadr F, Poizot-Martin I, Jacomet C, Pugliese P, Delobel P, Katlama C, Joly V, Chidiac C, Dournon N, Merrien D, May T, Reynes J, Gagneux-Brunon A, Chirouze C, Huleux T, Cabié A, Raffi F; Dat’AIDS study group.

PLoS One. 2018 Sep 21;13(9):e0203895. doi: 10.1371/journal.pone.0203895. eCollection 2018.

14.

Interest of cytology combined with Xpert® HPV and Anyplex® II HPV28 Detection human papillomavirus (HPV) typing: differential profiles of anal and cervical HPV lesions in HIV-infected patients on antiretroviral therapy.

Nassereddine H, Charpentier C, Bucau M, Joly V, Bienvenu L, Davitian C, Abramowitz L, Benabderrahmane D, Kotelevets L, Chastre E, Lehy T, Walker F.

HIV Med. 2018 Nov;19(10):698-707. doi: 10.1111/hiv.12661. Epub 2018 Jul 30.

PMID:
30062761
15.

Contribution of brain imaging to the diagnosis of intracranial tuberculoma and other brain lesions in patients presenting with miliary tuberculosis.

Bleibtreu A, Grall N, Laissy JP, Rioux C, Strukov A, Lariven S, Yeni P, Yazdanpanah Y, Joly V.

Med Mal Infect. 2018 Dec;48(8):533-539. doi: 10.1016/j.medmal.2018.06.006. Epub 2018 Jul 13.

PMID:
30017477
16.

Presence of Human Papillomavirus (HPV) Apolipoprotein B Messenger RNA Editing, Catalytic Polypeptide-Like 3 (APOBEC)-Related Minority Variants in HPV-16 Genomes From Anal and Cervical Samples but Not in HPV-52 and HPV-58.

Mariaggi AA, Péré H, Perrier M, Visseaux B, Collin G, Veyer D, Le Hingrat Q, Ferré VM, Joly V, Couvelard A, Bucau M, Davitian C, Descamps D, Abramowitz L, Charpentier C.

J Infect Dis. 2018 Aug 24;218(7):1027-1036. doi: 10.1093/infdis/jiy287.

PMID:
29788374
17.

Usefulness of Kaposi's Sarcoma-Associated Herpesvirus (KSHV) DNA Viral Load in Whole Blood for Diagnosis and Monitoring of KSHV-Associated Diseases.

Jary A, Leducq V, Palich R, Gothland A, Descamps D, Joly V, Lambert-Niclot S, Amiel C, Canestri A, Mirand A, Gault E, Vabret A, Valantin MA, Katlama C, Calvez V, Dupin N, Spano JP, Marcelin AG.

J Clin Microbiol. 2018 May 25;56(6). pii: e00569-18. doi: 10.1128/JCM.00569-18. Print 2018 Jun. No abstract available.

18.

Risk of Progressive Multifocal Leukoencephalopathy in the Combination Antiretroviral Therapy Era in the French Hospital Database on Human Immunodeficiency Virus (ANRS-C4).

Melliez H, Mary-Krause M, Bocket L, Guiguet M, Abgrall S, De Truchis P, Katlama C, Martin-Blondel G, Henn A, Revest M, Robineau O, Khuong-Josses MA, Canestri A, De Castro N, Joly V, Mokhtari S, Risso K, Gasnault J, Costagliola D; French Hospital Database on HIV (ANRS-C4).

Clin Infect Dis. 2018 Jul 2;67(2):275-282. doi: 10.1093/cid/ciy074.

PMID:
29635465
19.

High virological suppression regardless of the genotypic susceptibility score after switching to a dolutegravir-based regimen: week 48 results in an observational cohort.

Charpentier C, Peytavin G, Lê MP, Joly V, Cabras O, Perrier M, Le Gac S, Phung B, Yazdanpanah Y, Descamps D, Landman R.

J Antimicrob Chemother. 2018 Jun 1;73(6):1665-1671. doi: 10.1093/jac/dky062.

PMID:
29528412
20.

Deciphering the Evolution and Development of the Cuticle by Studying Lipid Transfer Proteins in Mosses and Liverworts.

Salminen TA, Eklund DM, Joly V, Blomqvist K, Matton DP, Edqvist J.

Plants (Basel). 2018 Jan 15;7(1). pii: E6. doi: 10.3390/plants7010006. Review.

21.

Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen.

Raffi F, Hanf M, Ferry T, Khatchatourian L, Joly V, Pugliese P, Katlama C, Robineau O, Chirouze C, Jacomet C, Delobel P, Poizot-Martin I, Ravaux I, Duvivier C, Gagneux-Brunon A, Rey D, Reynes J, May T, Bani-Sadr F, Hoen B, Morrier M, Cabie A, Allavena C; Dat’AIDS Study Group.

J Antimicrob Chemother. 2017 Dec 1;72(12):3502. doi: 10.1093/jac/dkx383. No abstract available.

PMID:
29121210
22.

Prevalence of gag mutations associated with in vitro resistance to capsid inhibitor GS-CA1 in HIV-1 antiretroviral-naive patients.

Perrier M, Bertine M, Le Hingrat Q, Joly V, Visseaux B, Collin G, Landman R, Yazdanpanah Y, Descamps D, Charpentier C.

J Antimicrob Chemother. 2017 Oct 1;72(10):2954-2955. doi: 10.1093/jac/dkx208. No abstract available.

PMID:
29091184
23.

No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir.

Perrier M, Visseaux B, Landman R, Joly V, Todesco E, Yazdanpanah Y, Calvez V, Marcelin AG, Descamps D, Charpentier C.

J Antimicrob Chemother. 2018 Jan 1;73(1):173-176. doi: 10.1093/jac/dkx366.

PMID:
29077926
24.

Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen.

Raffi F, Hanf M, Ferry T, Khatchatourian L, Joly V, Pugliese P, Katlama C, Robineau O, Chirouze C, Jacomet C, Delobel P, Poizot-Martin I, Ravaux I, Duvivier C, Gagneux-Brunon A, Rey D, Reynes J, May T, Bani-Sadr F, Hoen B, Morrier M, Cabie A, Allavena C; Dat’AIDS Study Group.

J Antimicrob Chemother. 2017 Dec 1;72(12):3425-3434. doi: 10.1093/jac/dkx300. Erratum in: J Antimicrob Chemother. 2017 Dec 1;72(12):3502.

PMID:
28961719
25.

Epidemiology of autoimmune and inflammatory diseases in a French nationwide HIV cohort.

Lebrun D, Hentzien M, Cuzin L, Rey D, Joly V, Cotte L, Allavena C, Dellamonica P, Servettaz A, Bani-Sadr F; the Dat’AIDS study group.

AIDS. 2017 Sep 24;31(15):2159-2166. doi: 10.1097/QAD.0000000000001603.

PMID:
28723711
26.

Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study.

Gantner P, Cuzin L, Allavena C, Cabie A, Pugliese P, Valantin MA, Bani-Sadr F, Joly V, Ferry T, Poizot-Martin I, Garraffo R, Peytavin G, Fafi-Kremer S, Rey D; Dat'AIDS study group.

HIV Med. 2017 Oct;18(9):704-708. doi: 10.1111/hiv.12506. Epub 2017 Apr 26. No abstract available.

27.

Initiation of Antiretroviral Therapy Containing Integrase Inhibitors Increases the Risk of IRIS Requiring Hospitalization.

Dutertre M, Cuzin L, Demonchy E, Puglièse P, Joly V, Valantin MA, Cotte L, Huleux T, Delobel P, Martin-Blondel G; DatʼAIDS Study Group.

J Acquir Immune Defic Syndr. 2017 Sep 1;76(1):e23-e26. doi: 10.1097/QAI.0000000000001397. No abstract available.

PMID:
28418992
28.

A rare fungal infection: Phaehyphomycosis due to Veronaea botryosa and review of literature.

Welfringer A, Vuong V, Argy N, Chochillon C, Deschamps L, Rollin G, Harent S, Joly V, Vindrios W, Descamps V.

Med Mycol Case Rep. 2017 Feb 5;15:21-24. doi: 10.1016/j.mmcr.2017.02.001. eCollection 2017 Mar.

29.

Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort.

Perrier M, Charpentier C, Peytavin G, Lê M, Blondel L, Visseaux B, Joly V, Pinto A, Matheron S, Yazdanpanah Y, Descamps D, Landman R.

J Antimicrob Chemother. 2017 Jun 1;72(6):1745-1751. doi: 10.1093/jac/dkx018.

PMID:
28186251
30.

Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study.

Madelain V, Le MP, Champenois K, Charpentier C, Landman R, Joly V, Yeni P, Descamps D, Yazdanpanah Y, Peytavin G.

J Antimicrob Chemother. 2017 Apr 1;72(4):1137-1146. doi: 10.1093/jac/dkw527.

31.

18FDG-PET/CT: a useful tool for the management of patients in infectious diseases.

Pichon M, Mikail N, Ben Ali K, Rouzet F, Burdet C, Yazdanpanah Y, Joly V, Lepage L, Sarda-Mantel L.

Infect Dis (Lond). 2017 Feb;49(2):155-157. Epub 2016 Sep 12. No abstract available.

PMID:
27619910
32.

Abacavir has no prothrombotic effect on platelets in vitro.

Diallo YL, Ollivier V, Joly V, Faille D, Catalano G, Jandrot-Perrus M, Rauch A, Yeni P, Ajzenberg N.

J Antimicrob Chemother. 2016 Dec;71(12):3506-3509. Epub 2016 Aug 11.

PMID:
27516475
33.

Epidemiological Profile of Newly Diagnosed HIV-Infected Patients in Northern Paris: A Retrospective Study.

Senard O, Burdet C, Visseaux B, Charpentier C, Le Gac S, Julia Z, Lariven S, Descamps D, Yazdanpanah Y, Yeni P, Joly V.

AIDS Res Hum Retroviruses. 2017 Jan;33(1):11-16. doi: 10.1089/AID.2016.0036. Epub 2016 Sep 7.

PMID:
27476681
34.

Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).

Slama L, Landman R, Assoumou L, Benalycherif A, Samri A, Joly V, Pialoux G, Valin N, Cabié A, Duvivier C, Lambert-Niclot S, Marcelin AG, Peytavin G, Costagliola D, Girard PM; IMEA 040 DATA Study Group.

J Antimicrob Chemother. 2016 Aug;71(8):2252-61. doi: 10.1093/jac/dkw103. Epub 2016 Apr 10.

PMID:
27068399
35.

The Plant Ovule Secretome: A Different View toward Pollen-Pistil Interactions.

Liu Y, Joly V, Dorion S, Rivoal J, Matton DP.

J Proteome Res. 2015 Nov 6;14(11):4763-75. doi: 10.1021/acs.jproteome.5b00618. Epub 2015 Oct 2.

PMID:
26387803
36.

Endocarditis due to gram-negative bacilli at a French teaching hospital over a 6-year period: clinical characteristics and outcome.

Loubet P, Lescure FX, Lepage L, Kirsch M, Armand-Lefevre L, Bouadma L, Lariven S, Duval X, Yazdanpanah Y, Joly V.

Infect Dis (Lond). 2015;47(12):889-95. Epub 2015 Aug 11.

PMID:
26260729
37.

Use of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-Up.

Charpentier C, Lê MP, Joly V, Visseaux B, Lariven S, Phung B, Yéni P, Yazdanpanah Y, Descamps D, Peytavin G, Landman R.

PLoS One. 2015 Jul 30;10(7):e0134430. doi: 10.1371/journal.pone.0134430. eCollection 2015.

38.

Complications following intravesical bacillus Calmette-Guerin treatment for bladder cancer: a case series of 22 patients.

Pommier JD, Ben Lasfar N, Van Grunderbeeck N, Burdet C, Laouénan C, Rioux C, Pierre-Audigier C, Meybeck A, Choudat L, Benchikh A, Nguyen S, Bouvet E, Yeni P, Yazdanpanah Y, Joly V.

Infect Dis (Lond). 2015;47(10):725-31. doi: 10.3109/23744235.2015.1055794. Epub 2015 Jun 16.

PMID:
26077036
39.

Isolated blepharoptosis may point to HIV-associated Burkitt's lymphoma.

Pichon M, Savatovsky J, Lamirel C, Joly V, Moulignier A.

Acta Neurol Belg. 2015 Dec;115(4):833-5. doi: 10.1007/s13760-015-0463-7. Epub 2015 Apr 1. No abstract available.

PMID:
25828838
40.

KAPPA, a simple algorithm for discovery and clustering of proteins defined by a key amino acid pattern: a case study of the cysteine-rich proteins.

Joly V, Matton DP.

Bioinformatics. 2015 Jun 1;31(11):1716-23. doi: 10.1093/bioinformatics/btv047. Epub 2015 Jan 31.

PMID:
25638812
41.

[An update on measles].

Caseris M, Burdet C, Lepeule R, Houhou N, Yeni P, Yazdanpanah Y, Joly V.

Rev Med Interne. 2015 May;36(5):339-45. doi: 10.1016/j.revmed.2014.10.362. Epub 2015 Jan 8. Review. French.

PMID:
25579464
42.

The FRK1 mitogen-activated protein kinase kinase kinase (MAPKKK) from Solanum chacoense is involved in embryo sac and pollen development.

Lafleur E, Kapfer C, Joly V, Liu Y, Tebbji F, Daigle C, Gray-Mitsumune M, Cappadocia M, Nantel A, Matton DP.

J Exp Bot. 2015 Apr;66(7):1833-43. doi: 10.1093/jxb/eru524. Epub 2015 Jan 8.

43.

Time to initiation of antiretroviral therapy in HIV-infected patients diagnosed with an opportunistic disease: a cohort study.

Deconinck L, Yazdanpanah Y, Gilson RJ, Melliez H, Viget N, Joly V, Sabin CA.

HIV Med. 2015 Apr;16(4):219-29. doi: 10.1111/hiv.12201. Epub 2014 Dec 18.

44.

Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay.

Charpentier C, Choquet M, Joly V, Yeni P, Visseaux B, Caseris M, Brun-Vézinet F, Yazdanpanah Y, Peytavin G, Descamps D, Landman R.

J Antimicrob Chemother. 2014 Oct;69(10):2819-25. doi: 10.1093/jac/dku211. Epub 2014 Jun 19.

PMID:
24948705
45.

Change in HIV-1 DNA tropism despite virological success in patients receiving an enfuvirtide-based regimen.

Charpentier C, Joly V, Ghosn J, Yeni P, Raffi F, Descamps D, Morand-Joubert L.

J Antimicrob Chemother. 2014 Sep;69(9):2588-90. doi: 10.1093/jac/dku155. Epub 2014 May 9. No abstract available.

PMID:
24816213
46.

French 2010-2011 measles outbreak in adults: report from a Parisian teaching hospital.

Caseris M, Houhou N, Longuet P, Rioux C, Lepeule R, Choquet C, Yazdanpanah Y, Yeni P, Joly V.

Clin Microbiol Infect. 2014 Apr;20(4):O242-4. doi: 10.1111/1469-0691.12384. Epub 2013 Oct 30.

47.

Magnetic edge-states in nanographene, HNO3-doped nanographene and its residue compounds of nanographene-based nanoporous carbon.

Hao SJ, Joly VL, Kaneko S, Takashiro J, Takai K, Hayashi H, Enoki T, Kiguchi M.

Phys Chem Chem Phys. 2014 Apr 7;16(13):6273-82. doi: 10.1039/c4cp00199k.

PMID:
24569838
48.

Clinical activity of lenalidomide in visceral human immunodeficiency virus-related Kaposi sarcoma.

Steff M, Joly V, Di Lucca J, Feldman J, Burg S, Sarda-Mantel L, Peytavin G, Marinho E, Crickx B, Raymond E, Lariven S, Maubec E.

JAMA Dermatol. 2013 Nov;149(11):1319-22. doi: 10.1001/jamadermatol.2013.5751.

PMID:
24080749
49.

Antiretroviral treatments in 2012: improvements and future prospects.

Charpentier C, Joly V, Yeni P, Brun-Vézinet F.

Virologie (Montrouge). 2013 Jun 1;17(3):182-192. doi: 10.1684/vir.2013.0502.

PMID:
31910545
50.

Predictive value of liver enzymes and inflammatory biomarkers for the severity of liver fibrosis stage in HIV/HCV co-infected patients.

Charpentier C, Champenois K, Gervais A, Landman R, Joly V, Le Gac S, Larrouy L, Damond F, Brun-Vézinet F, Descamps D, Yazdanpanah Y.

PLoS One. 2013;8(3):e59205. doi: 10.1371/journal.pone.0059205. Epub 2013 Mar 19.

Supplemental Content

Support Center